Aster DM Quality Care Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Kerala recovery drives the quarter: The cluster delivered its highest-ever quarterly revenue of INR 620 Cr, up 24% QoQ, with EBITDA margins expanding to 26.8%, anchoring the consolidated margin recovery.
• Consolidated margins rebound sharply: Operating EBITDA margin expanded 200 bps QoQ to 22%, driven by Kerala’s turnaround, cost discipline, and a Labs business that swung from near-breakeven to 17.8% margins.
• QCIL integration is delivering ahead of plan: Post-merger synergies in procurement and F&B, plus a 280 bps payor mix shift toward cash and insurance, pushed QCIL’s standalone EBITDA margin up 130 bps YoY to 24.1%.
• The growth mix is shifting toward complex, high-ticket care: Oncology revenue share rose to 11% from 9%, driving a 10% YoY ARPP (IP) increase, while seasonal, low-acuity volumes fell 12% across India, compressing the apparent top-line growth rate.
• What to watch next quarter: Whether the Andhra & Telangana cluster sustains its QoQ margin doubling, the pace of ramp-up at the newly commissioned Kasaragod hospital, and any NCLT filing progress on the QCIL merger.

Kerala Turnaround: The Quarter’s Core Engine

• Volume and value both inflected: Inpatient volumes grew 13% QoQ, MVT rebounded 67% QoQ, and occupancy improved from 64% to 69%, while ARPP (IP) rose 5% on a richer specialty mix and more complex procedures.
• Profitability followed the mix shift: Unlike Q2 FY25, when vector-borne disease drove high volumes in pulmonology, internal medicine, and pediatrics, this quarter’s growth came from quality electives and surgical cases, lifting margins to 26.8% from 22.3% in Q4 FY25.
• The recovery is broad-based, not just Medcity: Kannur’s margins moved beyond 20%, Medcity added 100 beds and is inching toward INR 90-100 Cr monthly revenue with margins above 30%, and unit-level leadership has stabilized, enabling manpower and material consumption efficiencies.
• MVT is a material contributor: International patient footfall grew 67% QoQ, led by Maldives, the Middle East (especially Oman), and North African countries, supported by a new pan-India MVT leadership structure with cluster-wise focus.

Alisha Moopen: "The Kerala cluster's journey over the past year has been one of transformation and resilience... The true inflection came in Q2 FY26, when Kerala delivered its highest-ever quarterly revenue of INR 620 Crore."

QCIL Performance: Synergies and Self-Help

• Standalone momentum is strong: QCIL revenue grew 15.1% YoY to INR 1,193 Cr, post-Ind AS EBITDA rose 21.6% YoY to INR 287 Cr, and margins expanded 130 bps to 24.1%, driven by ARPP growth, volume expansion, and a richer CONGO-T mix.
• Synergy execution is ahead of plan: Procurement centralization and F&B in-sourcing, implemented in H2 FY25, are already contributing to EBITDA growth, alongside the ramp of the Nagercoil unit launched in October 2024.
• The unit-level segmentation tells the story: Mature units (60% of revenue) delivered 14.4% YoY revenue growth and 27.4% YoY EBITDA growth at a 33.2% margin; focus units (29% of revenue) recorded 30.4% QoQ EBITDA growth; emerging units (6% of revenue) grew EBITDA 90.1% QoQ.
• Payor mix is a structural margin lever: Cash and insurance payor share moved up 240 bps YoY to 81%, which is margin-accretive, and management sees room to continue improving it.
• ALOS reduction adds to ARPP: ALOS fell 6% YoY from 4.08 to 3.85 days through tighter clinical protocols, directly lifting per-bed revenue.

Varun Khanna: "The fact that we've been able to move the payor mix by 280 basis points is phenomenal. I think there is business focus and operating focus, and when you do things right, you're able to grow the right payor pretty well."

Margin Bridge: What Drove the 200 bps QoQ Expansion

• Overhead and manpower efficiencies led: Centralized procurement, renewable energy adoption, and operating leverage delivered ~100 bps of overhead reduction, while manpower cost efficiencies contributed ~30 bps.
• Material costs partially offset the gains: An ~80 bps increase in material costs came from Oncology growth (up 26% YoY), particularly immunotherapy and targeted therapy in the medical oncology mix, and from lower vector-borne disease incidence, which shifted the case mix toward higher material-cost specialties.
• Labs swung from drag to contributor: Operating margins in Labs improved to 17.8% from 7.6% in Q1 FY26 and 11.0% in Q2 FY25, driven by 31% YoY growth in external business, enhanced operating leverage, and improved material cost efficiencies, with ROCE reaching 23% from negative levels a year ago.
• GST and CGHS changes largely offset: The GST rate reduction on IP medicines from 12% to 5% created a ~35-40 bps EBITDA headwind from revenue loss on pharmacy margins, but the first CGHS price increase in over a decade (covering 2,000+ procedures) on ~INR 20 Cr monthly revenue delivered a roughly equivalent positive impact, with 75-80% flowing to EBITDA.
• Karnataka and Maharashtra margins lagged the recovery: EBITDA grew only 6% YoY despite 10% revenue growth, because the shift to medical oncology at Whitefield increased material costs from immunotherapy and targeted therapy, and a 26% seasonal de-growth in internal medicine, pulmonology, and pediatrics meant growth came disproportionately from high-material-cost CONGO-T specialties.

Growth Drivers and the Specialty Mix Shift

• Oncology is becoming the dominant growth vector: Oncology revenue share rose to 11% from 9% YoY, with 60% of that from medical oncology and 40-50% of medical oncology revenue from immunotherapy and targeted therapies, which carry high material costs but also high ticket sizes.
• Seasonal headwinds mask underlying momentum: Internal medicine, pulmonology, and pediatrics saw a 12% de-growth across India, with Karnataka hit hardest at 26%, which is why mid-teens or higher teen growth is not visible in the consolidated numbers despite strong elective and surgical volumes.
• Whitefield is the standout in Karnataka: The hospital grew 27% YoY, with oncology contributing 17% of Karnataka cluster revenue, while Aster CMI posted single-digit growth but is gaining traction in north Bangalore.
• ARPOB growth has multiple structural drivers: ALOS reduction contributes ~5% directly, the discontinuation of low-yield schemes at Aadhar/Kolhapur removed 1,500-1,600 patients and lifted ARPP, and the seasonal mix shift toward CONGO-T specialties further elevated the metric, making ARPP (IP) the preferred measure going forward.

Sunil Kumar: "I think we should start moving out of ARPOB and move to the more of a ARPP (IP) also."

Expansion and the Merger Pathway

• Kasaragod is live and ramping: The 264-bed hospital commissioned on October 2, 2025, with 100 beds opened, average daily OPD footfall exceeding 150, 50+ doctors onboard, and 7-10 admissions per day, positioned as a higher tertiary care center with medical and surgical oncology.
• The bed pipeline is substantial: Plans to add 2,300+ beds through greenfield and brownfield projects will take total capacity beyond 7,800 beds, with QCIL alone investing ~INR 2,000 Cr to add over 1,700 beds in 3-4 years, ~1,300 of them in non-metro and Tier-2 markets.
• Merger is progressing through regulatory milestones: No-objection letters received from BSE and NSE with no adverse observations, CCI approval granted, the strategic share swap completed (5% stake in QCIL for 3.6% preferential allotment in Aster), and the company will now approach NCLT, with headquarters shifting from Bangalore to Hyderabad for single-state approval efficiency.
• Greenfield drag is expected to be manageable: The Sarjapur project is coming at the end of H2 FY27, with capital deployment around mid-year, and management expects merger synergies to absorb any margin impact rather than creating a visible drag.
• Andhra and Telangana strategy is still being defined: With majority stake now secured in Aster Ramesh Hospitals, market studies are underway and proposals are under review, but management said it is too early to share a strategy and will come back "maybe in the next couple of quarters."

Varun Khanna: "Tier 2 markets, if done right, the opportunity to scale them up fast is, in my opinion, better than many Tier 1 markets."

Guidance & Commitments

Key Metrics